| Dr Jordan Michael Katz, MD | |
|
2500 Ridge Ave Ste 107, Evanston, IL 60201-2468 | |
| (224) 364-4503 | |
| Not Available |
| Full Name | Dr Jordan Michael Katz |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 7 Years |
| Location | 2500 Ridge Ave Ste 107, Evanston, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972023000 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 036.119704 (Illinois) | Secondary |
| 207Q00000X | Family Medicine | 036.119704 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northshore University Healthsystem - Evanston Hospital | Evanston, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Shore University Healthsystem Faculty Practice Associates | 2163334699 | 1751 |
News Archive
Boehringer Ingelheim announced today that the European Commission has approved an update to the Summary of Product Characteristics (SmPC) for VIRAMUNE (nevirapine) in the treatment of patients with HIV.
Democrats may be feeling smug about their campaign against the House Republican budget plan, and as a matter of politics, they're no doubt right. If the goal is to deal with the long-term fiscal challenge, though, the Democrats' political success is apt only to prolong the gridlock and make the eventual solution that much more painful. ...
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
› Verified 5 days ago
| Entity Name | Erie Family Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760499545 PECOS PAC ID: 9537050422 Enrollment ID: O20040322000689 |
News Archive
Boehringer Ingelheim announced today that the European Commission has approved an update to the Summary of Product Characteristics (SmPC) for VIRAMUNE (nevirapine) in the treatment of patients with HIV.
Democrats may be feeling smug about their campaign against the House Republican budget plan, and as a matter of politics, they're no doubt right. If the goal is to deal with the long-term fiscal challenge, though, the Democrats' political success is apt only to prolong the gridlock and make the eventual solution that much more painful. ...
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
› Verified 5 days ago
| Entity Name | Northshore University Healthsystem Faculty Practice Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497701882 PECOS PAC ID: 2163334699 Enrollment ID: O20040524000118 |
News Archive
Boehringer Ingelheim announced today that the European Commission has approved an update to the Summary of Product Characteristics (SmPC) for VIRAMUNE (nevirapine) in the treatment of patients with HIV.
Democrats may be feeling smug about their campaign against the House Republican budget plan, and as a matter of politics, they're no doubt right. If the goal is to deal with the long-term fiscal challenge, though, the Democrats' political success is apt only to prolong the gridlock and make the eventual solution that much more painful. ...
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
› Verified 5 days ago
| Entity Name | Esperanza Health Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124187125 PECOS PAC ID: 2961453105 Enrollment ID: O20050204000750 |
News Archive
Boehringer Ingelheim announced today that the European Commission has approved an update to the Summary of Product Characteristics (SmPC) for VIRAMUNE (nevirapine) in the treatment of patients with HIV.
Democrats may be feeling smug about their campaign against the House Republican budget plan, and as a matter of politics, they're no doubt right. If the goal is to deal with the long-term fiscal challenge, though, the Democrats' political success is apt only to prolong the gridlock and make the eventual solution that much more painful. ...
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jordan Michael Katz, MD 450 E Romie Ln, Salinas, CA 93901-4029 Ph: (831) 759-3257 | Dr Jordan Michael Katz, MD 2500 Ridge Ave Ste 107, Evanston, IL 60201-2468 Ph: (224) 364-4503 |
News Archive
Boehringer Ingelheim announced today that the European Commission has approved an update to the Summary of Product Characteristics (SmPC) for VIRAMUNE (nevirapine) in the treatment of patients with HIV.
Democrats may be feeling smug about their campaign against the House Republican budget plan, and as a matter of politics, they're no doubt right. If the goal is to deal with the long-term fiscal challenge, though, the Democrats' political success is apt only to prolong the gridlock and make the eventual solution that much more painful. ...
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
› Verified 5 days ago
Dr. Elizabeth Feldman, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1285 Hartrey Ave, Evanston, IL 60202 Phone: 312-666-3494 | |
Jennifer Callegari Hill, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 2650 Ridge Ave Ste 1304, Evanston, IL 60201 Phone: 847-657-1840 | |
Emily C White Vangompel, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1285 Hartrey Ave, Evanston, IL 60202 Phone: 847-666-3494 | |
Michael Jeng-ming Tu, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 1325 Howard St, Suite 200, Evanston, IL 60202 Phone: 312-423-4200 Fax: 847-905-0490 | |
Dr. Zulfikar Esmail, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1616 Forest Pl, Evanston, IL 60201 Phone: 847-328-5596 | |
Dr. Alvin Au-yeung, DO, MPH Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2650 Ridge Ave Ste 1304, Evanston, IL 60201 Phone: 847-866-7846 Fax: 847-657-1893 | |
Dr. Nicole Elizabeth Bogdanovich, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2650 Ridge Ave, Suite 1304, Evanston, IL 60201 Phone: 847-363-0504 |